Bristol and Pfizer Anticlotting Drug Gets FDA Priority Review

The FDA announced it would give priority review to Eliquis, an anticlotting drug produced by Bristol-Myers Squibb and Pfizer, according to a Wall Street Journal report.

Advertisement

The drug works to prevent strokes in people with a heart-rhythm disorder called atrial fibrillation. An FDA decision could come as early as March 28, 2012.

Related Articles on FDA Approvals:
FDA Approves Expansion of BioMarin Pharma Plant
FDA Approves Philips’ PET and MRI Whole Body Scanning System
FDA Approves New Boston Scientific Heart Stent

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.